Valuation: Exelixis, Inc.

Market Cap 14.49B 12.62B 11.95B 10.85B 20.28B 1,388B 20.38B 142B 55.02B 705B 54.44B 53.23B 2,258B P/E 2026 *
18.1x
P/E 2027 * 14.9x
Enterprise Value 13.75B 11.97B 11.33B 10.3B 19.24B 1,317B 19.33B 135B 52.2B 669B 51.65B 50.5B 2,142B EV / Sales 2026 *
5.39x
EV / Sales 2027 * 4.44x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 week+2.11%
Current month+7.95%
1 month+11.87%
3 months+10.77%
6 months+41.62%
Current year+32.86%
1 week 47.23
Extreme 47.23
50.7
1 month 44.22
Extreme 44.225
51.86
3 years 17.94
Extreme 17.935
51.86
5 years 13.88
Extreme 13.885
51.86
10 years 8.74
Extreme 8.735
51.86
Manager TitleAgeSince
Chief Executive Officer 65 22/07/2010
Director of Finance/CFO 58 15/07/2015
Chief Operating Officer 63 01/02/2016
Director TitleAgeSince
Director/Board Member 70 01/02/2004
Director/Board Member 82 01/08/2004
Chairman 77 01/01/1998
Change 5-day change 1-year change 3-year change Capi.($)
+2.31%+2.11%+50.49%+144.00% 14.49B
+1.76%+3.88%+46.85%+101.12% 70.89B
+2.29%+1.43%+38.39%+77.03% 62.32B
+1.14%-2.59%-14.37%+365.92% 27.07B
+2.95%+2.34%+0.52%-12.74% 24.78B
+1.49%+7.73%+26.85%-15.89% 20.59B
-0.83%-9.47%+174.16%+295.44% 15.52B
+3.01%+1.85%+44.63%+168.18% 14.49B
+2.43%+4.24%-2.05%+847.59% 14.14B
+1.00%+0.24%+28.02%+203.83% 12.35B
Average +1.69%+1.64%+39.35%+217.45% 29.13B
Weighted average by Cap. +1.83%+2.50%+37.19%+162.09%

Financials

2026 *2027 *
Net sales 2.55B 2.22B 2.1B 1.91B 3.57B 244B 3.59B 25.06B 9.69B 124B 9.59B 9.38B 398B 2.9B 2.53B 2.39B 2.17B 4.06B 278B 4.08B 28.47B 11.01B 141B 10.89B 10.65B 452B
Net income 821M 715M 677M 615M 1.15B 78.6B 1.15B 8.06B 3.12B 39.94B 3.08B 3.01B 128B 1.01B 882M 835M 758M 1.42B 96.95B 1.42B 9.94B 3.84B 49.27B 3.8B 3.72B 158B
Net Debt -744M -648M -614M -558M -1.04B -71.3B -1.05B -7.31B -2.83B -36.24B -2.8B -2.73B -116B -1.62B -1.41B -1.34B -1.22B -2.27B -155B -2.28B -15.93B -6.16B -78.98B -6.1B -5.96B -253B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
-
Date Price Change
17/09/26 €50.46 +2.31%
16/09/26 €49.32 +0.17%
15/09/26 €49.24 +1.32%
14/09/26 €48.60 +0.67%
11/09/26 €48.27 -2.32%
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
58.49USD
Average target price
53.69USD
Spread / Average Target
-8.21%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!